Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORF-057 in Moderately to Severely Active Crohn's Disease
NCT06226883Phase 2Recruiting
- Sponsor
- Morphic Therapeutic
- Start
- Jul 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 2, randomised, double-blind trial of LY4268989 in Crohn's disease (6 arms), sponsored by Morphic Therapeutic. Primary endpoint: Endoscopic response by Simple Endoscopic Score-CD (SES-CD) at 14 weeks. Started Jul 2024; status: recruiting.
02
Drugs
LY4268989
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06226883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226883.